Design of C3201-HSA functional study.

<p>The study consisted of a four week acclimation period, four once weekly doses of C3201-HSA and a three week wash out period. Dates for collecting blood draws are indicated. These samples were tested for blood chemistry, C3201-HSA concentration and presence of anti-drug antibody. Body weight was determined once per week on the day that the animals were dosed. Forty animals were randomly assigned to four groups of ten. Group one was treated with Avimer vehicle (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2). Group two was treated with a low dose of C3201-HSA (0.5 mg/kg/week, weeks 1 and 2, 1 mg/kg/week, weeks 3 and 4). Group three was treated with a high dose of C3201-HSA (2.5 mg/kg/week, weeks 1 and 2, 5 mg/kg/week, weeks 3 and 4). Group four was treated with of a positive control long-acting FGF21 variant Fc-FGF21 with a 3 mg/kg dose once per week.